Join
Live feed
·
PRReleasevia Quantisnow
Vir Biotechnology Inc. logo

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

ByQuantisnow·Wall Street's wire, on your screen.
VIR· Vir Biotechnology Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VIR (Vir Biotechnology Inc.) and more on Quantisnow.